| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Febrile Neutropenia | 3 | 2023 | 16 | 2.130 |
Why?
|
| Syphilis, Congenital | 2 | 2025 | 9 | 1.720 |
Why?
|
| Anti-Bacterial Agents | 9 | 2025 | 880 | 1.470 |
Why?
|
| Bacteremia | 4 | 2022 | 110 | 1.410 |
Why?
|
| Hospitals, Pediatric | 3 | 2025 | 128 | 1.100 |
Why?
|
| Sepsis | 2 | 2023 | 402 | 1.090 |
Why?
|
| Penicillins | 1 | 2025 | 25 | 0.880 |
Why?
|
| Tertiary Care Centers | 3 | 2024 | 131 | 0.870 |
Why?
|
| Clostridium Infections | 3 | 2023 | 132 | 0.780 |
Why?
|
| Blood Culture | 2 | 2020 | 13 | 0.760 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2023 | 74 | 0.720 |
Why?
|
| Neoplasms | 3 | 2023 | 3349 | 0.710 |
Why?
|
| Hypotension | 1 | 2022 | 77 | 0.690 |
Why?
|
| Publishing | 1 | 2022 | 97 | 0.680 |
Why?
|
| Staphylococcal Infections | 2 | 2017 | 287 | 0.660 |
Why?
|
| Pandemics | 3 | 2022 | 914 | 0.660 |
Why?
|
| Public Health | 1 | 2022 | 161 | 0.660 |
Why?
|
| Cross Infection | 5 | 2025 | 155 | 0.650 |
Why?
|
| Child | 19 | 2025 | 7750 | 0.630 |
Why?
|
| Fever | 5 | 2022 | 121 | 0.600 |
Why?
|
| Infant, Newborn | 9 | 2026 | 2551 | 0.600 |
Why?
|
| Pneumonia, Necrotizing | 1 | 2017 | 1 | 0.510 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 3 | 2019 | 26 | 0.490 |
Why?
|
| Staphylococcus aureus | 2 | 2010 | 292 | 0.480 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 85 | 0.460 |
Why?
|
| Bacteria | 1 | 2020 | 546 | 0.460 |
Why?
|
| Infection Control | 5 | 2025 | 134 | 0.450 |
Why?
|
| Humans | 48 | 2026 | 98370 | 0.440 |
Why?
|
| Neutrophils | 3 | 2020 | 346 | 0.400 |
Why?
|
| Retrospective Studies | 9 | 2025 | 11043 | 0.390 |
Why?
|
| Pregnancy Complications, Parasitic | 2 | 2026 | 17 | 0.380 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2026 | 8 | 0.370 |
Why?
|
| Virulence Factors | 2 | 2010 | 117 | 0.370 |
Why?
|
| Child, Preschool | 13 | 2025 | 4042 | 0.370 |
Why?
|
| Leadership | 4 | 2021 | 160 | 0.360 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2009 | 5 | 0.360 |
Why?
|
| Hemolysin Proteins | 2 | 2009 | 32 | 0.360 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2024 | 100 | 0.350 |
Why?
|
| Infant | 7 | 2025 | 3361 | 0.340 |
Why?
|
| Bacterial Toxins | 2 | 2009 | 112 | 0.340 |
Why?
|
| Pregnancy | 5 | 2026 | 3269 | 0.330 |
Why?
|
| Adhesins, Bacterial | 1 | 2010 | 37 | 0.320 |
Why?
|
| Bacterial Adhesion | 1 | 2010 | 84 | 0.320 |
Why?
|
| Adolescent | 11 | 2025 | 10140 | 0.310 |
Why?
|
| Proteoglycans | 1 | 2010 | 76 | 0.300 |
Why?
|
| Membrane Transport Proteins | 1 | 2010 | 169 | 0.290 |
Why?
|
| Communicable Diseases | 1 | 2010 | 74 | 0.290 |
Why?
|
| Lung Diseases | 2 | 2009 | 284 | 0.290 |
Why?
|
| Chemokines, CXC | 1 | 2008 | 22 | 0.290 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 32 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 602 | 0.280 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2020 | 151 | 0.280 |
Why?
|
| Actinomycosis | 1 | 2008 | 12 | 0.270 |
Why?
|
| United States | 9 | 2025 | 8262 | 0.270 |
Why?
|
| Syndecans | 1 | 2007 | 4 | 0.270 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 250 | 0.260 |
Why?
|
| HIV Infections | 1 | 2017 | 1018 | 0.250 |
Why?
|
| Drug Utilization | 2 | 2018 | 65 | 0.250 |
Why?
|
| Guideline Adherence | 2 | 2021 | 250 | 0.250 |
Why?
|
| Leishmania mexicana | 1 | 2026 | 2 | 0.250 |
Why?
|
| Critical Care | 2 | 2022 | 462 | 0.240 |
Why?
|
| Male | 17 | 2025 | 47263 | 0.240 |
Why?
|
| Disease Outbreaks | 2 | 2017 | 149 | 0.240 |
Why?
|
| Shock, Septic | 2 | 2023 | 135 | 0.240 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2026 | 36 | 0.230 |
Why?
|
| Female | 18 | 2026 | 51761 | 0.230 |
Why?
|
| Health Personnel | 2 | 2021 | 257 | 0.230 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2005 | 1 | 0.230 |
Why?
|
| Paragonimiasis | 1 | 2005 | 1 | 0.230 |
Why?
|
| Hand Hygiene | 2 | 2025 | 13 | 0.230 |
Why?
|
| Appendicitis | 1 | 2006 | 70 | 0.230 |
Why?
|
| Health Information Systems | 1 | 2025 | 7 | 0.220 |
Why?
|
| Placenta | 1 | 2026 | 202 | 0.210 |
Why?
|
| Caregivers | 2 | 2025 | 200 | 0.210 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2024 | 11 | 0.210 |
Why?
|
| Child, Hospitalized | 1 | 2025 | 38 | 0.210 |
Why?
|
| Personal Protective Equipment | 2 | 2021 | 41 | 0.210 |
Why?
|
| Nursing Homes | 1 | 2025 | 109 | 0.210 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 686 | 0.200 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 67 | 0.200 |
Why?
|
| Triage | 1 | 2025 | 151 | 0.200 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2023 | 26 | 0.190 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 112 | 0.190 |
Why?
|
| Aftercare | 1 | 2023 | 92 | 0.180 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 87 | 0.180 |
Why?
|
| Critical Pathways | 1 | 2022 | 36 | 0.180 |
Why?
|
| Monocytes | 1 | 2023 | 220 | 0.180 |
Why?
|
| Inflammation | 2 | 2008 | 1133 | 0.180 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 60 | 0.170 |
Why?
|
| Burns | 1 | 2023 | 150 | 0.160 |
Why?
|
| Inpatients | 2 | 2021 | 367 | 0.160 |
Why?
|
| Machine Learning | 1 | 2025 | 410 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 479 | 0.160 |
Why?
|
| Infliximab | 2 | 2019 | 169 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2025 | 1100 | 0.160 |
Why?
|
| Patient Discharge | 1 | 2023 | 381 | 0.150 |
Why?
|
| Neutropenia | 1 | 2020 | 211 | 0.150 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 11 | 0.150 |
Why?
|
| Klebsiella Infections | 1 | 2019 | 35 | 0.140 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 37 | 0.140 |
Why?
|
| Syndecan-1 | 2 | 2009 | 18 | 0.140 |
Why?
|
| Expert Testimony | 1 | 2018 | 34 | 0.140 |
Why?
|
| Logistic Models | 1 | 2022 | 1276 | 0.140 |
Why?
|
| Chagas Disease | 1 | 2018 | 4 | 0.140 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 27 | 0.140 |
Why?
|
| Leishmaniasis | 1 | 2017 | 5 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 894 | 0.130 |
Why?
|
| Adult | 6 | 2026 | 29587 | 0.130 |
Why?
|
| Directly Observed Therapy | 1 | 2017 | 5 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2022 | 450 | 0.130 |
Why?
|
| Health Resources | 1 | 2018 | 80 | 0.130 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 22 | 0.130 |
Why?
|
| Meglumine | 1 | 2017 | 36 | 0.130 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 30 | 0.130 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2017 | 27 | 0.130 |
Why?
|
| HIV Antibodies | 1 | 2017 | 40 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1752 | 0.120 |
Why?
|
| Drug Overdose | 1 | 2018 | 103 | 0.120 |
Why?
|
| Vancomycin | 1 | 2017 | 78 | 0.120 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2025 | 125 | 0.120 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 6 | 0.120 |
Why?
|
| Sorbitol | 1 | 2016 | 9 | 0.120 |
Why?
|
| Foodborne Diseases | 1 | 2016 | 9 | 0.120 |
Why?
|
| Young Adult | 4 | 2026 | 7568 | 0.120 |
Why?
|
| Organometallic Compounds | 1 | 2017 | 142 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 38 | 0.120 |
Why?
|
| Acute Disease | 1 | 2017 | 860 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 314 | 0.110 |
Why?
|
| Genotype | 1 | 2019 | 1892 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 156 | 0.100 |
Why?
|
| Social Media | 1 | 2016 | 119 | 0.100 |
Why?
|
| Education, Medical | 1 | 2016 | 229 | 0.100 |
Why?
|
| Epidermal Cyst | 1 | 2013 | 6 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 176 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 977 | 0.100 |
Why?
|
| Meningitis | 1 | 2013 | 22 | 0.100 |
Why?
|
| Escherichia coli | 1 | 2016 | 572 | 0.100 |
Why?
|
| Physician's Role | 1 | 2015 | 181 | 0.100 |
Why?
|
| Mexico | 2 | 2026 | 76 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 4044 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 542 | 0.090 |
Why?
|
| Prognosis | 1 | 2020 | 4126 | 0.090 |
Why?
|
| Brain Diseases | 1 | 2013 | 178 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2015 | 357 | 0.090 |
Why?
|
| Animals | 7 | 2010 | 28981 | 0.090 |
Why?
|
| Aspirin | 2 | 2014 | 168 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 3032 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2010 | 733 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2014 | 255 | 0.070 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2009 | 20 | 0.070 |
Why?
|
| Chemokines | 1 | 2008 | 79 | 0.070 |
Why?
|
| Enterotoxins | 1 | 2008 | 22 | 0.070 |
Why?
|
| Lung Injury | 1 | 2009 | 61 | 0.070 |
Why?
|
| Brain Abscess | 1 | 2007 | 8 | 0.070 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2007 | 16 | 0.070 |
Why?
|
| Leishmania | 2 | 2017 | 7 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1570 | 0.060 |
Why?
|
| Foreign Bodies | 1 | 2007 | 62 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2010 | 676 | 0.060 |
Why?
|
| Endemic Diseases | 1 | 2026 | 7 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2678 | 0.060 |
Why?
|
| Bronchi | 1 | 2007 | 229 | 0.060 |
Why?
|
| Praziquantel | 1 | 2005 | 1 | 0.060 |
Why?
|
| Anthelmintics | 1 | 2005 | 7 | 0.060 |
Why?
|
| Risk Factors | 3 | 2023 | 6273 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2026 | 284 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 3616 | 0.050 |
Why?
|
| Chicago | 2 | 2019 | 1519 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2025 | 112 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1290 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 763 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2025 | 387 | 0.050 |
Why?
|
| Health Facilities | 1 | 2023 | 43 | 0.050 |
Why?
|
| Bandages | 1 | 2023 | 43 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2023 | 83 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2025 | 415 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2025 | 523 | 0.040 |
Why?
|
| Parents | 1 | 2025 | 323 | 0.040 |
Why?
|
| Child Care | 1 | 2021 | 6 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2025 | 430 | 0.040 |
Why?
|
| Hand Disinfection | 1 | 2021 | 18 | 0.040 |
Why?
|
| Personnel, Hospital | 1 | 2021 | 31 | 0.040 |
Why?
|
| Invasive Fungal Infections | 1 | 2020 | 10 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2026 | 2056 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 215 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 149 | 0.040 |
Why?
|
| Mice | 3 | 2009 | 12735 | 0.040 |
Why?
|
| Critical Illness | 1 | 2023 | 361 | 0.040 |
Why?
|
| Molecular Typing | 1 | 2019 | 19 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 12 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 195 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 62 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 171 | 0.030 |
Why?
|
| Medical Audit | 1 | 2018 | 43 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2019 | 234 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 165 | 0.030 |
Why?
|
| Epidemiologists | 1 | 2017 | 1 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 394 | 0.030 |
Why?
|
| Public Health Practice | 1 | 2017 | 11 | 0.030 |
Why?
|
| Public Health Administration | 1 | 2017 | 19 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 408 | 0.030 |
Why?
|
| Resource Allocation | 1 | 2017 | 65 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 63 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 2599 | 0.030 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 132 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 122 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2016 | 63 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 194 | 0.030 |
Why?
|
| Drug Costs | 1 | 2017 | 66 | 0.030 |
Why?
|
| Food Service, Hospital | 1 | 2016 | 4 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 676 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 970 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 876 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 335 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2015 | 51 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1393 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 992 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 784 | 0.030 |
Why?
|
| Viruses | 1 | 2015 | 64 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 2009 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 525 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 988 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2014 | 124 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2015 | 219 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 43 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1945 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2014 | 182 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2792 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 720 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1787 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 3228 | 0.020 |
Why?
|
| Physicians | 1 | 2018 | 685 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 687 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2010 | 84 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1419 | 0.020 |
Why?
|
| Craniotomy | 1 | 2007 | 100 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 994 | 0.020 |
Why?
|
| Drainage | 1 | 2007 | 176 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2007 | 182 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1110 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1607 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 891 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2050 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 9770 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 1408 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 2212 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 1334 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 3633 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 29532 | 0.010 |
Why?
|